149 related articles for article (PubMed ID: 22548342)
1. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
[TBL] [Abstract][Full Text] [Related]
5. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
Pomel V; Klicic J; Covini D; Church DD; Shaw JP; Roulin K; Burgat-Charvillon F; Valognes D; Camps M; Chabert C; Gillieron C; Françon B; Perrin D; Leroy D; Gretener D; Nichols A; Vitte PA; Carboni S; Rommel C; Schwarz MK; Rückle T
J Med Chem; 2006 Jun; 49(13):3857-71. PubMed ID: 16789742
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
7. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.
Ward SE; Harries M; Aldegheri L; Andreotti D; Ballantine S; Bax BD; Harris AJ; Harker AJ; Lund J; Melarange R; Mingardi A; Mookherjee C; Mosley J; Neve M; Oliosi B; Profeta R; Smith KJ; Smith PW; Spada S; Thewlis KM; Yusaf SP
J Med Chem; 2010 Aug; 53(15):5801-12. PubMed ID: 20614889
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
10. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
11. SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.
Bell K; Sunose M; Ellard K; Cansfield A; Taylor J; Miller W; Ramsden N; Bergamini G; Neubauer G
Bioorg Med Chem Lett; 2012 Aug; 22(16):5257-63. PubMed ID: 22819766
[TBL] [Abstract][Full Text] [Related]
12. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.
Laleu B; Gaggini F; Orchard M; Fioraso-Cartier L; Cagnon L; Houngninou-Molango S; Gradia A; Duboux G; Merlot C; Heitz F; Szyndralewiez C; Page P
J Med Chem; 2010 Nov; 53(21):7715-30. PubMed ID: 20942471
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
[TBL] [Abstract][Full Text] [Related]
15. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S
J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.
Oka Y; Yabuuchi T; Oi T; Kuroda S; Fujii Y; Ohtake H; Inoue T; Wakahara S; Kimura K; Fujita K; Endo M; Taguchi K; Sekiguchi Y
Bioorg Med Chem; 2013 Dec; 21(24):7578-83. PubMed ID: 24262886
[TBL] [Abstract][Full Text] [Related]
17. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.
Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Hamilton E; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Scullion P; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Bruin J; Hamilton W; Uitdehaag J; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
Bioorg Med Chem Lett; 2010 Mar; 20(5):1524-7. PubMed ID: 20149657
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750
[TBL] [Abstract][Full Text] [Related]
19. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
[TBL] [Abstract][Full Text] [Related]
20. From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
Barth M; Bondoux M; Luccarini JM; Peyrou V; Dodey P; Pruneau D; Massardier C; Paquet JL
J Med Chem; 2012 Mar; 55(6):2574-84. PubMed ID: 22369198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
